FDA approves new hepatitis C combination treatment.
The Wall Street Journal (12/19, Loftus, Subscription Publication) reported that the FDA approved AbbVie Inc.’s new treatment for hepatitis C, called Viekira Pak, after clinical trials showed that more than 90% of people with the most common subtype of hepatitis C in the US, Genotype 1, were cured. Viekira Pak consists of three new medicines, paritaprevir, ombitasvir and dasabuvir, in addition to one older drug, ritonavir. The treatment regimen will reportedly cost $83,319 per patient for the standard 12-week treatment, which is below the price tags on either of Gilead Science Inc.’s hepatitis C treatments: Sovaldi (sofosbuvir) or Harvoni (ledipasvir and sofosbuvir), costing $84,000 and $94,500, respectively.
Hi-Dose Vitamin C IV infusions at about $100/infusion which has fewer side effects and likely better efficacy is a bargain price. Twice weekly IV VIt C infusions for a few months w/ Liposomal on days not infused.... Human clinical case reports show cure (Dr. T. Levy reports in his book "Primal Panacea")... for more visit www.PHC365.com
Source: From AMA Morning Rounds...